Echo IQ Secures Mayo Clinic Collaboration to Assess Cardiac Risk in Cancer Patients

Echo IQ (ASX: EIQ) has entered into a research collaboration with Mayo Clinic to evaluate its AI platform for cardiac risk stratification in oncology patients.

The study will assess whether routinely acquired echocardiographic data can generate predictive heart failure risk scores for patients undergoing cancer therapy.

The collaboration takes Echo IQ into the rapidly emerging cardio-oncology sector, where improving cancer survival rates have increased the focus on cardiovascular complications associated with treatment.

Earlier identification of patients at elevated cardiac risk may support more timely intervention and improve clinical outcomes, and the research will assess Echo IQ’s platform in a large and clinically important patient population beyond its current cardiovascular applications.

Cardiac Risk Study

The study will be conducted at Mayo Clinic Arizona under the direction of Dr Chadi Ayoub, where researchers will assess the ability of Echo IQ’s AI model to generate predictive heart failure risk scores from echocardiographic parameters collected during cancer treatment.

A secure container environment will allow the platform to process de-identified echocardiographic data without exposing patient information.

The work will examine whether AI-driven analysis of standard cardiac imaging can provide clinicians with actionable risk stratification at the point of care.

Echo IQ and Mayo Clinic intend to co-author a manuscript for peer-reviewed publication following completion of the study, which is expected during the first half of calendar year 2027.

Growing Clinical Focus

More than 20 million new cancer cases are diagnosed globally each year, with a substantial proportion of patients receiving cardiac monitoring during treatment.

As survival rates continue to improve, healthcare providers are placing greater emphasis on managing the long-term cardiovascular consequences of cancer therapy and identifying at-risk patients before symptoms emerge.

Echo IQ uses AI-driven technology and proprietary software to support decision-making in cardiology, with its platform already receiving US Food and Drug Administration (FDA) clearance for aortic stenosis and an application submitted to the FDA for heart failure to be given clearance as an indication.

“As cancer survival rates continue to improve, healthcare systems are increasingly focused on managing the long-term cardiac consequences of cancer therapy,” chief executive officer Dustin Haines said.

“We are excited by the prospect of assessing whether routinely acquired echocardiographic data can be used to generate meaningful predictive insights for clinicians.”